Omalizumab-Induced Arthralgias in a Patient with Chronic Idiopathic Urticaria
Main Article Content
Keywords
omalizumab, drug-induced arthralgia, chronic idiopathic urticaria, inflammatory arthralgia
Abstract
Background: Omalizumab (Xolair) is a recombinant DNA-derived humanized IgG1 κ monoclonal antibody that selectively binds to the high-affinity IgE receptor on the surface of mast cells and basophils, limiting release of mediators of the allergic response. It is the first monoclonal antibody approved for the treatment of refractory chronic idiopathic urticaria in patients over the age of 12 and has been shown to result in clinically significant improvement of itching and wheal formation in these patients. Rarely, inflammatory arthralgias can be a severe side effect of omalizumab.
Clinical Case: We report a case of a 38-year-old female patient with chronic idiopathic urticaria who responded well on a therapeutic dosage of omalizumab, but subsequently developed severe inflammatory arthralgias. We decreased her dosage and added methotrexate for complete resolution of her urticarial and arthritic symptoms.
Conclusion: In patients with concern for medication-induced inflammatory arthralgias, physicians should consider reducing or discontinuing omalizumab with consideration of patient goals for the treatment of chronic idiopathic urticaria. This article highlights the occurrence of inflammatory arthralgias as a side effect of omalizumab, the importance of eliciting patient goals and preferences for treatment, and proposes a solution to manage these arthralgias while appropriately treating symptoms in patients with chronic idiopathic urticaria.
References
2. Agache I, Rocha C, Pereira A, et al. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines. Allergy. 2021; 76: 59–70. doi.org: 10.1111/all.14547
3. Lesiak A, Bednarski IA, Maćkowska A, et al. Omalizumab for urticaria treatment in clinical practice: a case series. Postepy Dermatol Alergol. 2018;35(4):372-374. doi:10.5114/ada.2018.77666
4. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39(6):788-797. doi:10.1111/j.1365-2222.2009.03214.x
5. Carrillo DC, Borges MS, García E, Egea E, Serrano CD. Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review. World Allergy Organ J. 2014;7(1):72. Published 2014 Dec 31. doi:10.1186/s40413-014-0050-z
6. Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742-1750.e4. doi:10.1016/j.jaci.2015.12.1342
7. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101-109. doi:10.1016/j.jaci.2013.05.013
8. U.S. Food and Drug Administration. Xolair® (omalizumab) for injection, for subcutaneous use. 2016. Accessed February 17, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/103976s5225lbl.pdf.
9. Okanoue T, Sakamoto S, Itoh Y, et al.. Side effects of high-dose interferon therapy for chronic hepatitis C. Journal of Hepatology. 1996; 25 (3): 283-291.
10. Chang C, Gershwin ME. Drugs and autoimmunity--a contemporary review and mechanistic approach. J Autoimmun. 2010;34(3):J266-J275. doi:10.1016/j.jaut.2009.11.012
11. Kumar SS. Possible omalizumab-induced arthritis [published online May 20, 2019]. Rheumatology Consultant. https://www.aaaai.org/allergist-resources/ask-the-expert/answers/2023/arthritis
12. Di Bona D, Fiorino I, Taurino M, et al. Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study. Respir Med. 2017;130:55-60. doi:10.1016/j.rmed.2017.07.013
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.